Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ERSPC Latest Findings Confirm Increased Mortality Benefit from Prostate Cancer Testing

Published: Wednesday, April 04, 2012
Last Updated: Wednesday, April 04, 2012
Bookmark and Share
Extended follow up needed to establish full impact of screening.

The long-running European Randomized Study of Screening for Prostate Cancer (ERSPC) has published its 11-year follow-up results.  These add weight to their original findings by confirming that screening does significantly reduce death from prostate cancer.  Appearing in the New England Journal of Medicine, the study finds that a man who undergoes PSA testing will have his risk of dying from prostate cancer reduced by 29%.

By extending the patient follow-up to an average of 11 years, the study shows that 31% fewer men than previously indicated would need to be diagnosed with cancer to save one life.

As Prof Fritz Schroeder, the international coordinator of the ERSPC study, explained: “Extending the follow up period strengthens the argument for screening.  But it does not decide it.  Even so, the risk reduction trend in our study is promising and it is imperative that we continue the follow-up.   So far, only about 30% of all men in the study have died. If a larger reduction of prostate cancer mortality is seen by further extending the study beyond the current median of 11 years, we can determine with greater certainty whether the benefit of screening outweighs the disadvantages.”

The main downside to screening is over diagnosis ‒ the diagnosis of cancers that do not pose any threat to the patient because they are slow growing or ‘indolent’.  Separate ERSPC findings already confirm that approximately 30% of detected cancers are unlikely to progress and cause a patient’s death.  Even so, the patient has received a diagnosis of cancer and may face the side effects of ‘unnecessary’ treatment.

“Screening programmes for prostate cancer will not be feasible until the medical communities can confidently balance the risk of reducing death from prostate cancer with these unacceptably high levels over diagnosis and overtreatment,” added Prof Schroeder.

ERSPC is the world’s largest prostate cancer screening study and involves eight countries – Belgium, Finland, France, Italy, Netherlands, Spain, Sweden and Switzerland.  Participants in the randomised study totalled 182,000, of which 162,000 men contribute to the core age group 55 – 69 (on which the 2012 report in NEJM is based).   Men randomized to the group being offered screening were tested using the prostate specific antigen (PSA) marker, every two or four years with an average follow-up of 11 years. The cut-off value for deciding if further investigation was needed was set at a PSA level of 3.0 ng/ml or more.  Men with this reading were then offered a biopsy.

Compared with the USA, individual PSA testing started late in most European countries and meant that only a relatively small number of men taking part in the control arm of the ERSPC study had previously taken a PSA test. This makes the ERSPC study fundamentally different from the US-based Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial where there was a high contamination rate in the control arm with at least 44% of participants already PSA-tested prior to being randomized into the study. The PLCO study has been unable to demonstrate any difference in prostate cancer mortality between the two arms of the study.

Currently, the only way for men with potentially insignificant cancers to avoid what could be unnecessary is to direct them towards an Active Surveillance programme. This offers them regular check-ups while delaying, at least temporarily, invasive treatment.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
GI Problems in Autism May Originate in Genes
Gene linked to autism lowers serotonin activity in mice, slows movement in gut.
Fructose Alters Hundreds of Brain Genes
UCLA scientists report that diet rich in omega-3 fatty acids can reverse the damage.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Genetic Variants for Happiness Discovered
VU Amsterdam scientists have found a genetic overlap between happiness and depression.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!